Effect of the anti-diabetic drug metformin in hepatocellular carcinoma in vitro and in vivo

International Journal of Oncology

Volumn 45, Issue 1, 2014, Pages 322-332

  Miyoshi, Hisaaki ^a   Kato, Kiyohito ^a   Iwama, Hisakazu ^a   Maeda, Emiko ^a   Sakamoto, Teppei ^a   Fujita, Koji ^a   Toyota, Yuka ^a   Tani, Joji ^a   Nomura, Takako ^a   Mimura, Shima ^a   Kobayashi, Mitsuyoshi ^a   Morishita, Asahiro ^a   Kobara, Hideki ^a   Mori, Hirohito ^a   Yoneyama, Hirohito ^a   Deguchi, Akihiro ^a   Himoto, Takashi ^a   Kurokohchi, Kazutaka ^a   Okano, Keiichi ^a   Suzuki, Yasuyuki ^a   Murao, Koji ^a   Masaki, Tsutomu ^a   more..

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Hepatocellular carcinoma; Huh7; Metformin; microRNA

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN E; METFORMIN; MICRORNA; PROTEIN TYROSINE KINASE; ANTINEOPLASTIC AGENT;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER CELL CARCINOMA; M PHASE CELL CYCLE CHECKPOINT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; S PHASE CELL CYCLE CHECKPOINT; TREATMENT DURATION; TUMOR XENOGRAFT; ANIMAL; CELL CYCLE; DRUG EFFECTS; DRUG SCREENING; EXPERIMENTAL LIVER NEOPLASM; GENE EXPRESSION REGULATION; LIVER TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; METFORMIN; MICE; MICE, NUDE; MICRORNAS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902585445     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2419     Document Type: Article

References (42)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Venook AP, Papandreou C, Furuse J and de Guevara LL: The incidence and epidemiology of hepatocellular carcinoma: A global and regional perspective. Oncologist 15: 5-13, 2010.
3. Witters LA: The blooming of the French lilac. J Clin Invest 108: 1105-1107, 2001.
4. Barriere G, Tartary M and Rigaud M: Metformin: A rising star to fight the epithelial mesenchymal transition in oncology. Anticancer Agents Med Chem 13: 333-340, 2013.
5. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH and Huang YC: Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in taiwanese: A representative population prospective cohort study of 800,000 individuals. BMC Cancer 11: 20, 2011.
6. Ben Sahra I, Laurent K, Loubat A, et al: The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27: 3576-3586, 2008.
7. Brown KA, Hunger NI, Docanto M and Simpson ER: Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase. Breast Cancer Res Treat 123: 591-596, 2010.
8. Hosono K, Endo H, Takahashi H, et al: Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol Carcinog 49: 662-671, 2010.
9. Zhou XZ, Xue YM, Zhu B and Sha JP: Effects of metformin on proliferation of human colon carcinoma cell line SW-480. Nan Fang Yi Ke Da Xue Xue Bao 30: 1935-1938, 2010 (In Chinese).
10. Kato K, Gong J, Iwama H, et al: The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther 11: 549-560, 2012.
11. Kobayashi M, Kato K, Iwama H, et al: Antitumor effect of metformin in esophageal cancer: In vitro study. Int J Oncol 42: 517-524, 2012.
12. Qu Z, Zhang Y, Liao M, Chen Y, Zhao J and Pan Y: In vitro and in vivo antitumoral action of metformin on hepatocellular carcinoma. Hepatol Res 42: 922-933, 2012.
13. Landgraf P, Rusu M, Sheridan R, et al: A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 129: 1401-1414, 2007.
14. Ji J, Yamashita T, Budhu A, et al: Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 50: 472-480, 2009.
15. Callegari E, Elamin BK, Giannone F, et al: Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology 56: 1025-1033, 2012.
16. Masaki T, Shiratori Y, Rengifo W, et al: Hepatocellular carcinoma cell cycle: Study of long-evans cinnamon rats. Hepatology 32: 711-720, 2000.
17. 17. Masaki T, Shiratori Y, Rengifo W, et al: Cyclins and cyclin-dependent kinases: Comparative study of hepatocellular carcinoma versus cirrhosis. Hepatology 37: 534-543, 2003.
18. Masaki T, Tokuda M, Yoshida S, et al: Comparison study of the expressions of myristoylated alanine-rich C kinase substrate in hepatocellular carcinoma, liver cirrhosis, chronic hepatitis, and normal liver. Int J Oncol 26: 661-671, 2005.
19. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
20. Towbin H, Staehelin T and Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA 76: 4350-4354, 1979.
21. Workman P, Aboagye EO, Balkwill F, et al: Guidelines for welfare and use of animals in cancer research. Br J Cancer 102: 1555-1577, 2010.
22. D'Incalci M, Colombo T, Ubezio P, et al: The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer 39: 1920-1926, 2003.
23. Masaki T, Morishita A, Kurokohchi K and Kuriyama S: Multidisciplinary treatment of patients with hepatocellular carcinoma. Expert Rev Anticancer Ther 6: 1377-1384, 2006.
24. Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE and Thor AD: Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 8: 2031-2040, 2009.
25. Gong J, Morishita A, Kurokohchi K, et al: Use of protein array to investigate receptor tyrosine kinases activated in gastric cancer. Int J Oncol 36: 101-106, 2010.
26. Wang LW, Li ZS, Zou DW, Jin ZD, Gao J and Xu GM: Metformin induces apoptosis of pancreatic cancer cells. World J Gastroenterol 14: 7192-7198, 2008.
27. Verma A, Warner SL, Vankayalapati H, Bearss DJ and Sharma S: Targeting Axl and Mer kinases in cancer. Mol Cancer Ther 10: 1763-1773, 2011.
28. Guttridge KL, Luft JC, Dawson TL, Kozlowska E, Mahajan NP, Varnum B and Earp HS: Mer receptor tyrosine kinase signaling: Prevention of apoptosis and alteration of cytoskeletal architecture without stimulation or proliferation. J Biol Chem 277: 24057-24066, 2002.
29. Sainaghi PP, Castello L, Bergamasco L, Galletti M, Bellosta P and Avanzi GC: Gas6 induces proliferation in prostate carcinoma cell lines expressing the axl receptor. J Cell Physiol 204: 36-44, 2005.
30. Li S and Hu GF: Angiogenin-mediated rRNA transcription in cancer and neurodegeneration. Int J Biochem Mol Biol 1: 26-35, 2010.
31. Hisai H, Kato J, Kobune M, et al: Increased expression of angiogenin in hepatocellular carcinoma in correlation with tumor vascularity. Clin Cancer Res 9: 4852-4859, 2003.
32. Boyerinas B, Park SM, Hau A, Murmann AE and Peter ME: The role of let-7 in cell differentiation and cancer. Endocr Relat Cancer 17: F19-F36, 2010.
33. Takamizawa J, Konishi H, Yanagisawa K, et al: Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64: 3753-3756, 2004.
34. Yu F, Yao H, Zhu P, et al: Let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131: 1109-1123, 2007.
35. Akao Y, Nakagawa Y and Naoe T: Let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull 29: 903-906, 2006.
36. Fu TY, Chang CC, Lin CT, Lai CH, Peng SY, Ko YJ and Tang PC: Let-7b-mediated suppression of basigin expression and metastasis in mouse melanoma cells. Exp Cell Res 317: 445-451, 2011.
37. Zhu XM, Wu LJ, Xu J, Yang R and Wu FS: Let-7c microRNA expression and clinical significance in hepatocellular carcinoma. J Int Med Res 39: 2323-2329, 2011.
38. Johnson SM, Grosshans H, Shingara J, et al: RAS is regulated by the let-7 microRNA family. Cell 120: 635-647, 2005.
39. Lee YS and Dutta A: The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 21: 1025-1030, 2007.
40. Osada H and Takahashi T: Let-7 and miR-17-92: Small-sized major players in lung cancer development. Cancer Sci 102: 9-17, 2011.
41. Haybaeck J, Zeller N and Heikenwalder M: The parallel universe: MicroRNAs and their role in chronic hepatitis, liver tissue damage and hepatocarcinogenesis. Swiss Med Wkly 141: w13287, 2011.
42. Borel F, Konstantinova P and Jansen PL: Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol 56: 1371-1383, 2012.